Merimepodib

Overview

Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase ( IMPDH ) with broad spectrum antiviral activities.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Infection | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Dengue Virus | Products > Signaling Pathways > Flavivirus | Products > Signaling Pathways > HBV | Products > Signaling Pathways > HCV

Product Information

• Catalog No.: HY-13986
• CAS No.: 198821-22-6
• Molecular Formula: C23H24N4O6
• Molecular Weight: 452.46
• Purity: 99.27%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.53 mM); Clear solution
• Availability: In-stock

Source

Original product source